Clinical Trials Logo
  1. Home
  2. Malignant Tumor of Breast
  3. NCT04541225

Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

Breast Cancer Clinical Trial

Official title:
Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

Clinical Trial Summary

At the time of study termination, NUV-422-02 was a first-in-human, open-label, Phase 1 dose escalation study designed to evaluate the safety and efficacy of NUV-422. The study population comprised adults with recurrent or refractory high-grade gliomas (HGGs), metastatic breast cancer (mBC), with and without brain metastases, and recurrent or refractory metastatic castration-resistant prostate cancer (mCRPC). All patients self-administered NUV-422 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Advanced Breast Cancer
  • Advanced Breast Carcinoma
  • Breast Cancer
  • Breast Carcinoma
  • Breast Neoplasms
  • Breast Tumor
  • Cancer of Breast
  • Cancer of Prostate
  • Cancer of the Breast
  • Cancer of the Prostate
  • Carcinoma
  • Castrate Resistant Prostate Cancer
  • Castration Resistant Prostatic Neoplasms
  • Castration-resistant Prostate Cancer
  • Glial Cell Tumors
  • Glioblastoma
  • Glioma
  • Glioma, Malignant
  • Glioma, Mixed
  • Malignant Tumor of Breast
  • Metastatic Breast Cancer
  • Metastatic Breast Carcinoma
  • Neoplasms
  • Prostate Cancer
  • Prostate Neoplasm
  • Prostatic Cancer
  • Prostatic Neoplasms
  • Prostatic Neoplasms, Castration-Resistant
  • Recurrence
  • Recurrent Glioblastoma
Clinical Trial Details
NCT number NCT04541225
Study type Interventional
Source Nuvation Bio Inc.
Contact
Status Terminated
Phase Phase 1
Start date December 8, 2020
Completion date August 31, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A